Skip to main content

Table 1 Biochemical markers and characteristics (mean ± SD) of the male HIV-1 infected subjects with hypogonadism (group I); HIV-1 infected male eugonadal patients and healthy controls (significance between HIV-1 infected men of group I or II and controls * p < 0.05) (significance between hypogonadal and eugonadal patients # p < 0.05)

From: Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART)

Parameter Group I
(n = 32)
Group II
(n = 48)
Group III
(n = 20)
Range
  HIV-1
hypogonadism
HIV-1
eugonadism
Male, control  
Weight [kg] 71.4 ± 4.2 * 74.7 ± 3.6 78.5 ± 4.7  
Body mass index [kg/m2] 24.1 ± 2.2 24.9 ± 3.1 26.05 ± 5.5  
Age [yr] 39.1 ± 7.2 35.2 ± 4.3 35.4 ± 4.1  
Smoker [total] 10 30 5  
Unemployed [total] 8 15 0  
Heroin addict 4 0 0  
Cotrim [total] 15 23 0  
Tuberculostatica [total] 1 2 0  
CD4 cell count [total] 153.5 ± 56.2 *# 235.5 ± 37.5 * 890.0 ± 69.1 610-970 [total]
Prolactin [mIU/ml] 31.1 ± 3.7 27.4 ± 2.05 30.8 ± 5.3 20-50 [mIU/ml]
FSH [mIU/ml] 2.15 ± 1.4 *# 4.2 ± 3.1 3.6 ± 2.6 2.2-19.6 [mIU/ml]
LH [mIU/ml] 1.9 ± 2.5 *# 3.2 ± 2.2 3.2 ± 1.4 2.5-99.5 [mIU/ml]
Testosterone total [ng/dl] 149.2 ± 62.5 *# 601.0 ± 73.2 534.4 ± 45.8 300-1000 [ng/dl]